19. juni · proinvestor.com
NOVO: Det eneste som ikke må ske og kursgallop i HIMS
The compound structures, manufacturing processes, and AI models in this breach could command considerably more than $25 million from the right buyers - a well-funded biotech in a jurisdiction with flexible attitudes toward IP provenance, or an investment group interested in what Novo's internal competitive modelling reveals about their position relative to Eli Lilly.
Les artikkel
